Best of ASCO® Montreal 2024: Melanoma – Dr. Wilson Miller
OR
Co-Chairs
Dr. Jamil Asselah
Dr. Kim Ma
Speakers
Dr. Wilson Miller
Studies/trials discussed:
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).
- A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047)
- Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.
